-
1.发明授权Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides 失效源自血管内皮生长因子受体1的表位肽和含有这些肽的疫苗公开(公告)号：US08663647B2
公开(公告)日：2014-03-04
申请号：US13566933
申请日：2012-08-03
Applicant: Hideaki Tahara , Takuya Tsunoda , Masabumi Shibuya , Shuichi Nakatsuru
Inventor： Hideaki Tahara , Takuya Tsunoda , Masabumi Shibuya , Shuichi Nakatsuru
IPC: A61K39/08
Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
Abstract translation: 本发明提供了包含SEQ ID NO：1,23,32的氨基酸序列的免疫原性肽，以及包含其中1,2或几个氨基酸被取代或加入的上述氨基酸序列的肽，以及 具有细胞毒性T细胞诱导性，并且还提供用于治疗或预防包含这些肽的肿瘤的药物。 本发明的肽可用作疫苗。
-
公开(公告)号：US20080319178A1
公开(公告)日：2008-12-25
申请号：US12142613
申请日：2008-06-19
Applicant: Masabumi SHIBUYA
Inventor： Masabumi SHIBUYA
IPC: C12N15/18
CPC classification number: C07K14/52 , A61K38/00 , A61K48/00 , C07K2319/00
Abstract: An object of the present invention is to provide a chimera VEGF-E having a reduced antigenicity while maintaining the activity of VEGF-E. The present invention provides a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF rector-2) but does not bind to Flt-1 (VEGF receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein.
Abstract translation: 本发明的目的是提供具有降低的抗原性同时维持VEGF-E的活性的嵌合体VEGF-E。 本发明提供具有生长血管内皮细胞活性的嵌合体蛋白质，其通过将具有结合KDR（VEGF rector-2）但不结合的血管形成活性的VEGF类似蛋白质的一部分序列 与具有人衍生的VEGF类似蛋白质的相应序列的Flt-1（VEGF受体-1）。
-
公开(公告)号：US07052693B2
公开(公告)日：2006-05-30
申请号：US10160232
申请日：2002-06-04
Applicant: Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
Inventor： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
IPC: A61K39/395 , C07K16/00 , C07K16/28
CPC classification number: G01N33/57407 , A61K38/00 , C07K16/2803 , C07K16/2863 , C07K2317/24 , C12N2799/026 , G01N33/6863 , G01N33/6893 , G01N33/74
Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
Abstract translation: 本发明提供了与人VEGF受体Flt-1和细胞表面上表达人VEGF受体Flt-1的细胞免疫反应的抗体或肽，以及抑制人VEGF与人VEGF受体Flt结合的抗体或肽 -1。 它还提供了用于诊断或治疗其病态通过异常血管生成进行的疾病（例如实体瘤的增殖或转移，类风湿性关节炎中的关节炎，糖尿病性视网膜病，早产儿视网膜病，牛皮癣等）的手段。
-
4.发明申请EPITOPE PEPTIDES DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND VACCINES CONTAINING THESE PEPTIDES 失效从血管内皮生长因子受体1和含有这些肽的疫苗衍生的外源性肽公开(公告)号：US20110250219A1
公开(公告)日：2011-10-13
申请号：US13040177
申请日：2011-03-03
Applicant: Hideaki Tahara , Takuya Tsunoda , Masabumi Shibuya , Shuichi Nakatsuru
Inventor： Hideaki Tahara , Takuya Tsunoda , Masabumi Shibuya , Shuichi Nakatsuru
IPC: A61K39/00 , C07K7/08 , C12N5/071 , C12N15/85 , C12N5/0783 , A61P35/04 , A61P9/10 , A61P19/02 , A61P17/06 , A61P37/04 , A61P27/02 , C07K7/06 , A61P35/00
Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
Abstract translation: 本发明提供了包含SEQ ID NO：1,23,32的氨基酸序列的免疫原性肽，以及包含其中1,2或几个氨基酸被取代或加入的上述氨基酸序列的肽，以及 具有细胞毒性T细胞诱导性，并且还提供用于治疗或预防包含这些肽的肿瘤的药物。 本发明的肽可用作疫苗。
-
5.发明申请EPITOPE PEPTIDES DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND VACCINES CONTAINING THESE PEPTIDES 有权从血管内皮生长因子受体1和含有这些肽的疫苗衍生的外源性肽公开(公告)号：US20090214581A1
公开(公告)日：2009-08-27
申请号：US11816893
申请日：2006-02-17
Applicant: Hideaki Tahara , Takuya Tsunoda , Masabumi Shibuya , Shuichi Nakatsuru
Inventor： Hideaki Tahara , Takuya Tsunoda , Masabumi Shibuya , Shuichi Nakatsuru
Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
Abstract translation: 本发明提供了包含SEQ ID NO：1,23,32的氨基酸序列的免疫原性肽，以及包含其中1,2或几个氨基酸被取代或加入的上述氨基酸序列的肽，以及 具有细胞毒性T细胞诱导性，并且还提供用于治疗或预防包含这些肽的肿瘤的药物。 本发明的肽可用作疫苗。
-
Patent Agency Ranking
公开(公告)号：US20060034838A1
公开(公告)日：2006-02-16
申请号：US11250411
申请日：2005-10-17
Applicant: Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
Inventor： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
IPC: A61K39/395
CPC classification number: G01N33/57407 , A61K38/00 , C07K16/2803 , C07K16/2863 , C07K2317/24 , C12N2799/026 , G01N33/6863 , G01N33/6893 , G01N33/74
Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
-
公开(公告)号：US06986890B1
公开(公告)日：2006-01-17
申请号：US09453718
申请日：1999-12-03
Applicant: Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
Inventor： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
IPC: A61K39/395
CPC classification number: G01N33/57407 , A61K38/00 , C07K16/2803 , C07K16/2863 , C07K2317/24 , C12N2799/026 , G01N33/6863 , G01N33/6893 , G01N33/74
Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
-
公开(公告)号：US20050222423A1
公开(公告)日：2005-10-06
申请号：US10500135
申请日：2002-12-26
Applicant: Shuji Saito , Yoichiro Suga , Masakazu Sato , Masabumi Shibuya
Inventor： Shuji Saito , Yoichiro Suga , Masakazu Sato , Masabumi Shibuya
IPC: A61K31/198 , A61K31/343 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/403 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/4453 , A61K31/5375 , A61P3/00 , A61P9/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C235/38 , C07C255/60 , C07C311/46 , C07C317/40 , C07C323/41 , C07D209/76 , C07D261/14 , C07D263/32 , C07D271/10 , C07D277/28 , C07D277/38 , C07D277/42 , C07D277/62 , C07D295/26 , C07D307/91 , C07D311/14 , C07D333/34 , C07D413/02
CPC classification number: C07D271/10 , A61K31/198 , A61K31/343 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/403 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/4453 , A61K31/5375 , C07C235/38 , C07C255/60 , C07C311/46 , C07C317/40 , C07C323/41 , C07D209/76 , C07D261/14 , C07D263/32 , C07D277/28 , C07D277/38 , C07D277/42 , C07D277/62 , C07D295/26 , C07D307/91 , C07D311/14 , C07D333/34
Abstract: The following compounds useful as VEGF receptor antagonists and having excellent physical properties are provided. A carboxylic acid derivative represented by formula: wherein ring A represents a benzene ring, a naphthalene ring, or the like; W represents a C1-5 alkylene group; Z represents a single bond or a phenylene group; R1 and R2 are the same or different and each represents a hydrogen atom, a halogen atom, a C1-5 alkyl group or a C1-10 alkoxy group; R3 represents a hydrogen atom, a halogen atom, a C1-12 alkyl group, a C2-5 alkynyl group, a trifluoromethyl group, an acetylenyl group, a cyano group, a nitro group, —CH2—R6, —Y—R11, or the like; R4 represents a group represented by formula: and R5 represents a hydrogen atom or a C1-5 alkyl group, or a pharmaceutical acceptable salt of the derivative.
Abstract translation: 提供了可用作VEGF受体拮抗剂并具有优异物理性质的以下化合物。 由下式表示的羧酸衍生物：其中环A表示苯环，萘环等; W表示C 1-5亚烷基; Z表示单键或亚苯基; R 1和R 2相同或不同，各自表示氢原子，卤素原子，C 1-5烷基或 C 1-10烷氧基; R 3表示氢原子，卤素原子，C 1-12烷基，C 2-5炔基，三氟甲基 基团，乙炔基，氰基，硝基，-CH 2 2 -OR 6，-YR 11等; R 4表示由式表示的基团：R 5表示氢原子或C 1-5烷基，或药学上可接受的 衍生物的盐。
-
公开(公告)号：US20080187529A1
公开(公告)日：2008-08-07
申请号：US11277121
申请日：2006-03-21
Applicant: Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi shibuya
Inventor： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi shibuya
IPC: A61K39/395 , C07K16/18 , A61P43/00 , C12N15/00
CPC classification number: G01N33/57407 , A61K38/00 , C07K16/2803 , C07K16/2863 , C07K2317/24 , C12N2799/026 , G01N33/6863 , G01N33/6893 , G01N33/74
Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis A in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
Abstract translation: 本发明提供了与人VEGF受体Flt-1和细胞表面上表达人VEGF受体Flt-1的细胞免疫反应的抗体或肽，以及抑制人VEGF与人VEGF受体Flt结合的抗体或肽 -1。 它还提供了用于诊断或治疗其病态由异常血管生成进行的疾病的诊断或治疗，例如实体瘤的增殖或转移，类风湿性关节炎中的关节炎A，糖尿病性视网膜病，早产儿视网膜病，银屑病等。
-
10.发明授权Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides 失效源自血管内皮生长因子受体1的表位肽和含有这些肽的疫苗公开(公告)号：US08257711B2
公开(公告)日：2012-09-04
申请号：US13040177
申请日：2011-03-03
Applicant: Hideaki Tahara , Takuya Tsunoda , Masabumi Shibuya , Shuichi Nakatsuru
Inventor： Hideaki Tahara , Takuya Tsunoda , Masabumi Shibuya , Shuichi Nakatsuru
Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
Abstract translation: 本发明提供了包含SEQ ID NO：1,23,32的氨基酸序列的免疫原性肽，以及包含其中1,2或几个氨基酸被取代或加入的上述氨基酸序列的肽，以及 具有细胞毒性T细胞诱导性，并且还提供用于治疗或预防包含这些肽的肿瘤的药物。 本发明的肽可用作疫苗。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.021 seconds)
